September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.
3 citations
,
March 2002 in “Linchuang pifuke zazhi” This study analyzed clinical manifestations of dermatomyositis in 18 patients, reporting common symptoms such as skin rash, proximal muscle weakness, and elevated serum markers, with treatment typically involving prednisolone and hydroxychloroquine.
January 2002 in “대한피부과학회지” This study analyzed clinical manifestations in 18 dermatomyositis patients, noting that all exhibited skin rash and variable symptoms like itching and muscle weakness, with treatment involving prednisolone and hydroxychloroquine.
14 citations
,
September 2024 in “Arthritis & Rheumatology” In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.
January 2026 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” In this case report, a 62-year-old woman with suspected discoid lupus erythematosus experienced worsening skin and hair symptoms despite treatment with topical corticosteroids, immunomodulatory therapy, and hydroxychloroquine, leading to her referral to a tertiary dermatology center.